Pediatric Anesthesia Risks Require Collaborative Studies, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
No organization acting by itself can hope to study the neurological risks of anesthesia in infants and young children, the agency says.
You may also be interested in...
FDA’s Sedation Product Workshop Will Be A Solo Affair
The agency had previously solicited proposals that an outside body or bodies evaluate the issues and sponsor a conference, but has now decided to do the work for the May 3 event in-house, albeit with outside input.
Pediatric Researcher Expresses Frustration With FDA Delay On Ketamine Trial
K.J.S. "Sunny" Anand, director of critical care at Le Bonheur Children's Hospital, said he has been waiting two and a half years for the agency to clear an IND for the drug.
Pediatric Researcher Expresses Frustration With FDA Delay On Ketamine Trial
K.J.S. "Sunny" Anand, director of critical care at Le Bonheur Children's Hospital, said he has been waiting two and a half years for the agency to clear an IND for the drug.